Organon & Co. (OGN) to Issue Quarterly Dividend of $0.28 on December 12th

Organon & Co. (NYSE:OGN) declared a quarterly dividend on Thursday, October 31st,Zacks Dividends reports. Stockholders of record on Tuesday, November 12th will be paid a dividend of 0.28 per share on Thursday, December 12th. This represents a $1.12 dividend on an annualized basis and a dividend yield of 6.98%. The ex-dividend date of this dividend is Tuesday, November 12th.

Organon & Co. has a dividend payout ratio of 24.8% indicating that its dividend is sufficiently covered by earnings. Analysts expect Organon & Co. to earn $4.12 per share next year, which means the company should continue to be able to cover its $1.12 annual dividend with an expected future payout ratio of 27.2%.

Organon & Co. Price Performance

Organon & Co. stock opened at $16.04 on Friday. The firm has a market capitalization of $4.13 billion, a PE ratio of 3.18, a P/E/G ratio of 0.73 and a beta of 0.84. Organon & Co. has a 52 week low of $10.84 and a 52 week high of $23.10. The firm’s 50-day simple moving average is $18.76 and its 200 day simple moving average is $20.05. The company has a quick ratio of 1.17, a current ratio of 1.70 and a debt-to-equity ratio of 17.73.

Organon & Co. (NYSE:OGN) last announced its quarterly earnings results on Thursday, October 31st. The company reported $0.87 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.90 by ($0.03). Organon & Co. had a net margin of 20.30% and a return on equity of 644.70%. The business had revenue of $1.58 billion during the quarter, compared to analysts’ expectations of $1.56 billion. During the same period last year, the company earned $0.78 EPS. The firm’s revenue for the quarter was up 4.1% on a year-over-year basis. On average, equities research analysts predict that Organon & Co. will post 3.97 EPS for the current fiscal year.

Analysts Set New Price Targets

OGN has been the topic of several analyst reports. Evercore ISI raised shares of Organon & Co. to a “strong-buy” rating in a research note on Wednesday, September 18th. JPMorgan Chase & Co. cut shares of Organon & Co. from a “neutral” rating to an “underweight” rating and raised their target price for the stock from $18.00 to $20.00 in a research report on Friday, September 6th.

About Organon & Co.

Organon & Co develops and delivers health solutions through a portfolio of prescription therapies and medical devices within women's health in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, a daily pill used to prevent pregnancy; Marvelon, progestin and estrogen used as daily pills to prevent pregnancy; Follistim AQ, used to promote the development of multiple ovarian follicles in assisted reproduction technology procedures; Elonva, an ovarian follicle stimulant; Ganirelix Acetate Injection, an injectable antagonist; and Jada, for abnormal postpartum uterine bleeding or hemorrhage.